Financial & Business News

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In RxSight To Contact Him Directly To Discuss Their Options

S&P Global is a high-quality, wide-moat business with dominant positions in ratings, indices, and financial data, making it ideal for long-term investors. The company boasts strong recurring revenue, high margins, and robust free cash flow, supporting consistent shareholder returns and Dividend King status. Despite a fully priced valuation, S&P Global is fairly valued relative to its history and peers, justifying a measured long-term Buy rating.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In PubMatic To Contact Him Directly To Discuss Their Options

Bristol-Myers Squibb is a Strong Buy at current levels, with a $54 price target and attractive 5.2% dividend yield. The company's innovative growth portfolio is gaining traction, offsetting legacy declines and positioning BMY for a turnaround. Valuation is compelling: BMY trades at a deep discount to peers, with limited downside and strong profitability metrics.

Eight OPEC+ members say they will boost production by 137,000 barrels a day in October, beginning to roll back some voluntary cuts previously put in place.

Broadcom reportedly gains OpenAI as a new qualified XPU customer, spurring a reacceleration in the FY 2026 outlook. The market has already quickly lifted its optimism on the deal, as Broadcom progresses with another hyperscale-level customer win. Yet, with custom chips becoming a more critical growth driver for AVGO, how many more OpenAI-level customers can Broadcom depend on?

PATH remains a compelling Buy after the selloff, thanks to the durable demand for the legacy RPA offerings during the AI boom and the new Agentic AI monetization opportunities. The same has been observed in its bottoming retention rate of 108% along with the growing customer count, the higher FQ2'26 net new ARR, and the raised FY2026 ARR guidance. PATH's SaaS investment thesis has been made further compelling, thanks to the richer adj operating margins, the double-digits adj EPS growth in H1'26, and GAAP profitability seemingly not far away.

Pfizer (PFE 1.28%) is a fairly well-known drugmaker, with a name that even non-healthcare-oriented types would likely know. That's a testament to the company's longevity and its success as a business.

ASG trades at an appealing ~8% discount, offering investors seeking a more diversified, growth-focused closed-end fund an interesting entry level. The fund's multi-manager approach spans large-, mid-, and small-cap growth equities, but recent shifts have increased exposure to mega-cap 'Mag 7' tech names. ASG's distribution is tax-friendly and based on capital gains, but payout sustainability depends on market conditions to continue harvesting appreciation.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Flywire To Contact Him Directly To Discuss Their Options